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RANDOMIZED CONTROLLED TRIALS
Randomized Controlled Trial of Dual Antiplatelet Therapy in
Patients Undergoing Surgery for Critical Limb Ischemia
Anne Burdess, MB, ChB,* Alastair F. Nimmo, MD,† O. James Garden, MD,* John A. Murie, MD,‡
A. Raymond W. Dawson, MD,‡ Keith A. A. Fox, BSc (Hons), MB ChB, FRCP, FESC, FMed Sci,§
and David E. Newby, PhD§
Background and Objective: Patients with critical limb ischemia have a
perioperative cardiovascular morbidity comparable to patients with acute coro-
nary syndromes. We hypothesized that perioperative dual antiplatelet therapy
would improve biomarkers of atherothrombosis without causing unacceptable
bleeding in patients undergoing surgery for critical limb ischemia.
Methods: In a double-blind randomized controlled trial, 108 patients under-
going infrainguinal revascularization or amputation for critical limb ischemia
were maintained on aspirin (75 mg daily) and randomized to clopidogrel
(600 mg prior to surgery, and 75 mg daily for 3 days; n  50) or matched
placebo (n  58). Platelet activation and myocardial injury were assessed by
flow cytometry and plasma troponin concentrations, respectively.
Results: Clopidogrel reduced platelet-monocyte aggregation before surgery
(38%–30%; P  0.007). This was sustained in the postoperative period (P 
0.0019). There were 18 troponin-positive events (8 16.0% clopidogrel vs.
10 17.2% placebo; relative risk RR: 0.93, 95% confidence interval CI:
0.39–2.17; P  0.86). Half of troponin-positive events occurred preopera-
tively with clopidogrel causing a greater decline in troponin concentrations
(P  0.001). There was no increase in major life-threatening bleeding (7
14% vs. 6 10%; RR: 1.4, 95% CI: 0.49–3.76; P  0.56) or minor
bleeding (17 34% vs. 12 21%; RR 1.64, 95% CI: 0.87–3.1; P  0.12),
although blood transfusions were increased (28% vs. 12.6%, RR: 2.3, 95%
CI: 1.0–5.29; P  0.037).
Conclusions: In patients with critical limb ischemia, perioperative dual
antiplatelet therapy reduces biomarkers of atherothrombosis without causing
unacceptable bleeding. Large-scale randomized controlled trials are needed
to establish whether dual antiplatelet therapy improves clinical outcome in
high-risk patients undergoing vascular surgery.
(Ann Surg 2010;252: 37–42)
Patients with peripheral arterial disease have an increased risk ofadverse cardiovascular events,1 particularly in the perioperative
period.2 Myocardial injury is the commonest life-threatening com-
plication of vascular surgery with a reported incidence ranging from
8% to 40%.3–5 This is comparable to the cardiovascular risk of
patients presenting with an acute coronary syndrome: 30-day death
and reinfarction rate of 8% to 20%.6
In patients with peripheral arterial disease, prophylactic use of
the thienopyridine clopidogrel has modest additional secondary
preventative benefits in comparison to,7 or in combination with,8
aspirin. Combination aspirin and clopidigrel therapy is of major
benefit in reducing recurrent ischemic events in patients with acute
coronary syndromes.9 It is therefore reasonable to postulate that dual
antiplatelet therapy may have particular benefits in patients under-
going vascular surgery. However, many clinicians would question
the wisdom of dual antiplatelet therapy in the operative setting
because of the risk of increased peri-operative bleeding. The CURE
(Clopidogrel in Unstable angina to prevent Recurrent ischemic
Events) trial reported an overall relative risk reduction in cardiovas-
cular death, myocardial infarction, or stroke in patients undergoing
coronary artery bypass grafting following non-ST segment elevation
myocardial infarction, without an increase in major life-threatening
bleeding.10 However, the surgical subgroup was not prospectively
randomized and only a small proportion of patients received dual
antiplatelet therapy within 5 days of operation. Despite these limi-
tations, the trial proposed that the potential cardiovascular benefits
of dual antiplatelet therapy may outweigh the risks of bleeding in the
high-risk surgical patient.
Atherothrombosis is the major underlying cause of adverse
cardiovascular events. Platelets play a key role in this process and
are associated with both the inflammatory destabilization of athero-
sclerotic plaques, and thrombus generation.11,12 Platelet activation is
commonly assessed using aggregometry or detection of platelet
surface P-selectin expression following ex vivo agonist stimulation.
These approaches are artificial and may not truly reflect the status of
in vivo platelet activation because of the potential for in vitro
activation, and the rapid shedding of P-selectin from the platelet
surface.13 Activated platelets are rapidly cleared from the circulation
by monocytes and the quantification of platelet-monocyte aggre-
gates is now emerging as the “gold standard ” assessment for in vivo
platelet activation.14,15 We and others have demonstrated that plate-
let-monocyte aggregates are increased in those who smoke or have
diabetes mellitus as well as in patients with peripheral arterial
disease or an acute coronary syndrome.16–19
To date, there have been no studies to investigate the effects
of dual antiplatelet therapy in patients undergoing surgery for
critical limb ischemia. Given the potential for both marked benefit
and hazard, we embarked upon a proof-of-concept pilot randomized
controlled trial. We hypothesized that combined perioperative aspi-
rin and clopidogrel therapy would improve biomarkers of athero-
thrombosis (platelet-monocyte aggregates and troponin release)
without causing unacceptable bleeding, in patients undergoing sur-
gery for critical limb ischemia.
From the Departments of *Clinical and Surgical Sciences, and †Anaesthesiology,
The University of Edinburgh, Edinburgh, United Kingdom; ‡Department of
Vascular Surgery, The Royal Infirmary of Edinburgh, Edinburgh, United
Kingdom; and §Centre for Cardiovascular Science, The University of Edin-
burgh, Edinburgh, United Kingdom.
Supported by grants from the British Heart Foundation (FS/05/038); European
Society of Vascular Surgery Research Awards; Royal College of Surgeons of
Edinburgh Research Grants and an unrestricted educational award from Sanofi
Aventis.
This study was registered on the ISRCT and EUDRA websites. International
Standardised RCT: ISRCTN22305120. Weblink: http://www.controlled-trials.
com/ISRCTN22305120.
Trial start date: June 1, 2005. Eudract Number: 2005–000960–25. CTA Number:
11449/0002/001–0001 (Granted 05/04/05). REC reference number: 05/
S0501/41 (Granted 29/04/05).
There was no involvement of Sanofi Aventis in any aspect of the trial including
protocol design, study conduct or data analysis.
Supplemental digital content is available for this article. Direct URL citations
appear in the printed text and are provided in the HTML and PDF versions of
this article on the journal’s Web site (www.annalsofsurgery.com).
Reprints: Anne Burdess, MB, ChB, Department of Clinical and Surgical Sciences,
The University of Edinburgh, Room SU304, The Chancellor’s Building, 49
Little France Crescent, Edinburgh, EH16 4SB, United Kingdom. E-mail:
anne.burdess@ed.ac.uk.
Copyright © 2010 by Lippincott Williams & Wilkins
ISSN: 0003-4932/10/25201-0037
DOI: 10.1097/SLA.0b013e3181e40dde
Annals of Surgery • Volume 252, Number 1, July 2010 www.annalsofsurgery.com | 37
METHODS
Subjects
Patients with critical limb ischemia who were scheduled for
infra-inguinal bypass, femoral endarterectomy or lower limb ampu-
tation under general anesthesia were recruited into the study. Critical
limb ischemia was defined as the presence of rest pain or skin
breakdown, resulting from arterial disease. Exclusion criteria in-
cluded women of child bearing potential, nonatherosclerotic vascu-
lar disease, sudden acute limb ischemia requiring emergency sur-
gery, supra-inguinal or aortic surgery, history of acute coronary
syndrome within 3 months, history of peptic ulcer disease, previous
or current intracranial hemorrhage, bleeding diathesis, uncontrolled
hypertension, or thrombocytopenia, planned epidural or spinal an-
esthesia, hypersensitivity or allergy to thienopyridines, and current
warfarin or thienopyridine use.
Study Design
Patients were recruited between June 2005 and February
2008, and gave written informed consent prior to study participation.
The study was approved by the local Research Ethics Committee,
given Clinical Trial Authorization by the Medicines and Healthcare
products Regulatory Agency (United Kingdom), and was conducted
in accordance with the Declaration of Helsinki and CONSORT
guidelines.20,21
This was a prospective single center double-blind randomized
controlled trial at a tertiary referral vascular surgical unit in the Royal
Infirmary of Edinburgh, South-East Scotland, United Kingdom.
Treatment Allocation
Following recruitment, clopidogrel and matched placebo
were assigned in identical packs by the pharmacy trials unit through
allocation of sequentially numbered study medication packs that had
been randomized using an independent computer-generated se-
quence. Patients received 600 mg of clopidogrel or matched placebo
4 to 28 hours prior to surgery and received 75 mg of clopidogrel or
matched placebo daily for 3 days after surgery (Studies suggest that
the incidence of peri-operative adverse cardiovascular events is
greatest within the first 5 days of surgery.2 We therefore commenced
therapy preoperatively and continued maintenance levels into a short
postoperative period.). Patients undergoing bypass procedures re-
ceived a single dose of 5000 IU of intravenous unfractioned heparin
during surgery before arterial clamping. At the discretion of the
clinical team, intravenous protamine was given only if excessive
bleeding was felt to be present at the end of the operation. All
patients received subcutaneous unfractionated heparin 5000 IU
twice daily in the postoperative period and were maintained on
aspirin (75 mg daily) throughout the study.
Biomarkers of Atherothrombosis
Platelet Activation and Inflammatory Markers
Blood samples were taken before, and a minimum of 4
hours after, a loading dose of 600 mg of clopiogrel or matched
placebo, immediately after the operation in the recovery room,
and on day 1 after surgery. Flow cytometric measurements of
platelet-monocyte aggregates and platelet surface expression of
P-selectin were used as markers of in vivo platelet activation as
described previously.16,17,19,22 Directly conjugated monoclonal
antibodies were obtained from DakoCytomation (Cambridge,
United Kingdom) and Serotec (Oxford, United Kingdom).
Myocardial Injury
The Reference Clinical Biochemistry Laboratory measured
plasma troponin I concentrations using the ARCHITECT Troponin
I STAT assay (Abbott Diagnostics, Maidenhead, United Kingdom)
using an autoanalyzer. This has an analytical sensitivity of 0.009
ng/mL and a functional sensitivity of 0.032 ng/mL with a coefficient
of variation of 10%. The latter threshold was employed for the
clinical case definition of myocardial infarction (see below).
In-Patient Clinical Outcomes
Acute Coronary Syndromes
Clinical symptoms, plasma troponin concentrations and elec-
trocardiograms were recorded daily from the preoperative day until
day 3 postsurgery. A blinded independent cardiologist reviewed all
clinical data and applied the universal definition of myocardial
infarction.23
Bleeding Complications
Bleeding events were defined as major (life-threatening or
nonlife threatening) and minor according to CURE criteria.10 Post-
operative blood transfusions were recommended according to Scot-
tish Intercollegiate Guidelines Network (SIGN) criteria.24 Intraop-
erative blood loss, postoperative fall in hemoglobin, blood product
transfusion, length of operation and length of hospital stay were
recorded. Incidence of gastro-intestinal bleeding, persistent (3
days) wound leak, hematoma, or infection were documented.
Data and Statistical Analysis
An independent data monitoring committee performed an
interim safety analysis of bleeding outcomes following recruitment
of 50 patients and recommended continuation of the trial to com-
pletion. Following completion of trial recruitment, data collection,
and laboratory analyses, the data base was locked, treatment allo-
cation unblinded and prespecified analyses performed. The primary
end-point was platelet-monocyte aggregation. The sample size (n 
50 per group) was based on our previous studies16,17,19 and gave an
80% power of detecting a 4.8% difference in platelet-monocyte
aggregates at a significance level of 5%. Secondary outcomes
included plasma troponin concentration, and rate of myocardial
infarction and bleeding complications. Continuous variables are
reported as mean  SD. Analysis of variance with repeated mea-
sures, 2-tailed Student t test and 2 analysis were performed as
appropriate using GraphPad Prism Version 4 (La Jolla, US). Statis-
tical significance was taken as a 2-sided P value 0.05.
Statement of Responsibility
The authors had full access to the data and take responsibility
for its integrity. All authors have read and agree to the manuscript as
written.
RESULTS
Of the 159 potentially eligible patients, 113 were randomized
to trial medication (Fig. 1). Of those who completed the study
protocol, 58 received placebo and 50 received clopidogrel. There
was no difference in baseline demographics between the 2 groups
(Table 1; Appendix 1, Supplemental Digital Content 1, online only,
available at: http://links.lww.com/SLA/A53).
Biomarkers of Atherothrombosis
Platelet Activation
In keeping with the patient population, baseline levels of
platelet-monocyte aggregation were markedly elevated. There was
no difference in baseline platelet-monocyte aggregates (P  0.80)
and P-selectin expression (P  0.80) between the 2 groups. Platelet
activation was unaffected by placebo (P  0.78) but clopidogrel
(600 mg) caused a rapid reduction in platelet-monocyte aggregates
(38%  17%–30%  17%, P  0.007) and platelet P-selectin
expression (4.9%  2.7%–2.8%  1.6%, P  0.0001). In both
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groups, platelet activation declined within 24 hours of surgery (P 
0.005), but clopidogrel treatment was associated with greater reduc-
tions throughout the immediate postoperative period (P  0.0019;
Fig. 2). To assess pharmacological efficacy of the trial intervention,
ex vivo platelet aggregation to 5 M adenosine diphosphate was
performed in a subgroup of trial participants (n  10 per group).
This confirmed that clopidogrel inhibited adenosine diphosphate-
induced aggregation (59%  20%–33%  18%, P  0.0001)
throughout the peri-operative period (P  0.0015; data not shown).
Myocardial Injury
Of the 108 trial subjects, 18 (16.7%) suffered an elevated
plasma troponin concentration (0.032 ng/mL): 8 (16.0%) received
clopidogrel and 10 (17.2%) placebo (relative risk RR 0.93, 95%
confidence intervals CI 0.40–2.17; P  0.86). Nine (8.3%) pa-
tients (4 clopidogrel and 5 placebo) had an elevation of plasma
troponin concentration before surgery, and 9 patients (4 clopidogrel
and 5 placebo) suffered a postoperative rise in troponin. Of those 9
FIGURE 2. Platelet-monocyte aggregates (squares; P
0.0001 for both groups) and platelet P-selectin expression
(circles; P  0.005 for both groups) over the perioperative
period in patients receiving placebo or clopidogrel. Clopi-
dogrel (closed symbols) caused a greater reduction in both
platelet-monocyte aggregates (P  0.0019) and platelet P-
selectin expression (P  0.0035) compared with placebo
(open symbols). Symbols represent mean  SD; analysis by
2-way ANOVA.
FIGURE 1. Trial profile.
TABLE 1. Baseline Characteristics of Patients According to
Interventional Group
Variable
Clopidogrel
n  50
Placebo
n  58 P
Age (yr) 68  2 68  2 0.83
Male sex 39 (78) 45 (78) 0.96
Critical limb ischemia
Ankle-brachial pressure index 0.2 34 (68) 31 (53) 0.12
Skin changes (ulcer/gangrene) 27 (54) 34 (59) 0.63
Rest pain 42 (84) 49 (84) 1.00
Operation
Bypass 32 41 0.71
Amputation 14 14 0.71
Combined bypass and angioplasty 4 3 0.71
Lees revised cardiac risk index 325 40 43 0.47
Cardiac risk factors
Diabetes mellitus 19 (38) 19 (33) 0.57
Hypertension 41 (82) 48 (83) 0.91
Hypercholesterolemia 31 (62) 37 (64) 0.85
Family history of ischemic heart
disease
5 (11) 8 (14) 0.55
Current smoker 20 (40) 31 (53) 0.36
Serum creatinine (mol/L) 98  4 106  6 0.27
Ischemic heart disease 20 (40) 31 (56) 0.16
Cerebrovascular disease 11 (22) 15 (26) 0.64
Drugs
Aspirin 50 (100) 58 (100) 1.00
Statin 35 (70) 45 (78) 0.37
Beta-blockade 13 (26) 12 (21) 0.43
Angiotensin-converting enzyme
inhibition
19 (38) 24 (41) 0.72
Variables reported as mean  SD or n (%) and analyzed with unpaired t test or 2
analysis as appropriate.
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patients who sustained a preoperative troponin rise, plasma troponin
concentrations fell with clopidogrel therapy but remained un-
changed or increased in those on placebo (Fig. 3). Patients with
postoperative elevation in plasma troponin concentrations had greater
platelet-monocyte aggregates (40% 4% vs. 30% 2%; P  0.033).
Clinical Outcomes
Of the 108 trial participants, 7 patients (6.5%) sustained an
acute myocardial infarction: 3 (6.0%) in the clopidogrel group and
4 (6.9%) in the placebo group (RR: 0.87, 95% CI: 0.20–3.7, P 
0.85). There were no in-patient deaths, intracranial hemorrhages or
incidences of inotrope use. There was no difference in life-threat-
ening major bleeding between treatment groups (7 14% clopi-
dogrel and 6 10% placebo; RR: 1.35, 95% CI: 0.49–3.76; P 
0.56), although those who received clopidogrel had an increased risk
of major nonlife-threatening bleeding (11 22% clopidogrel and 4
7% placebo, RR: 3.19, 95% CI: 1.1–9.4; P  0.024; Fig. 4).
Twenty (40%) patients receiving clopidogrel underwent red-cell
transfusion compared with only 8 (14%) on placebo (P  0.0019).
Restricting analyses to transfusions administered in accordance with
the SIGN guidelines, there remained an increased transfusion rate in
the clopidogrel group (14 28% clopidogrel and 7 12% placebo;
RR: 2.32, 95% CI: 1.02–5.29; P  0.037). There was no difference
in minor bleeding between the 2 groups (17 34% clopidogrel and
12 21% placebo; RR: 1.64, 95% CI: 0.87–3.10; P  0.12). Five
patients suffered gastrointestinal bleeding (hematemesis or ma-
laena); 4 of whom were receiving placebo. Two patients received
intraoperative protamine—1 in each intervention arm.
There were 2 reoperations for bleeding in the placebo group
and 1 in the clopidogrel group. Although there was an increase in
wound leak in those patients who received clopidogrel (13 26% vs.
3 5%; RR: 5.03, 95% CI: 1.52–16.6; P  0.0024), there was no
difference in incidence of wound infection at 3 months (P  0.80).
Clopidogrel therapy did not increase the length of operation (P 
0.60) or hospital stay (P  0.72). Subgroup analysis of patients
undergoing revascularization compared with amputation revealed no
significant differences in clopidogrel versus placebo in terms of
perioperative adverse cardiovascular events or bleeding outcomes
(major life threatening, major nonlife threatening or minor). There
were no incidences of early graft failure in either group.
DISCUSSION
We have conducted the first double-blind randomized con-
trolled trial of perioperative dual antiplatelet therapy in patients
undergoing surgery for critical limb ischemia. We demonstrate
improvements in biomarkers of platelet activation and myocardial
injury without causing unacceptable bleeding complications. These
data form the first objective assessment of the risks and benefits of
perioperative dual antiplatelet therapy in patients undergoing high-
risk vascular procedures.
Peripheral arterial disease affects nearly 30 million people in
Western Europe and North America. In up to 3-quarters of cases,
patients have coexistent coronary artery disease and a 3-fold in-
creased risk of cardiovascular events and death.26 In a recent large
FIGURE 3. Change in plasma troponin concentrations in pa-
tients with preoperative troponin elevations on placebo
(open squares) or clopidogrel (closed squares). Symbols rep-
resent mean  SD, P  0.001; 2-way ANOVA, clopidogrel
(n  4) versus placebo (n  5).
FIGURE 4. Bleeding Outcomes. Major life-threatening (upper
panel; RR: 1.35, 95% CI: 0.49–3.76, P  0.56), major non-
life-threatening (middle panel; RR: 3.19, 95% CI: 1.08–9.4,
P  0.024), and minor (RR: 1.64, 95% CI: 0.87–3.1, P 
0.12) bleeding (closed bars) in patients on clopidogrel (left-
hand panels, nonstippled) or placebo (right-hand panels,
stippled); 2 analysis.
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observational study (n  5460), patients with peripheral arterial
disease scheduled for open vascular surgery had a worse prognosis
(2.4-fold increase in cardiovascular morbidity) than matched pa-
tients with severe myocardial ischemia referred for percutaneous
coronary intervention.27 Interestingly, the occurrence of periopera-
tive cardiac complications following vascular surgery was associ-
ated with long-term cardiac death. There is therefore a clear unmet
need to reduce cardiovascular events in patients with peripheral
arterial disease, especially in the perioperative period.
In agreement with previous studies,2–5 we report a high
incidence of perioperative myocardial infarction (6.5%) and tropo-
nin elevation (16.7%) in patients undergoing surgery for critical
limb ischemia. We also found that postoperative elevations in
troponin were associated with increased levels of postoperative
platelet activation. However, we were surprised to find that markers
of platelet activation fell postoperatively (both in clopidogrel and
placebo groups) and that half of the troponin-positive events oc-
curred before surgery. This occurred in the absence of renal dys-
function. This suggests that rather than surgery being an additional
thrombotic stimulus, removal of ischemic tissue may actually reduce
platelet activation in the majority of these patients. These findings
highlight the prevalence of “silent” preoperative myocardial injury,
and the important systemic prothrombotic consequences of critical
limb ischemia, as well as the need for preoperative intervention.
This study aimed to explore a proof of concept. Preclinical
studies of platelet activation in coronary patients have informed the
design of large scale trials which have subsequently shaped clinical
practice. These trials required several thousands of patients to
demonstrate a small but significant clinical benefit from antiplatelet
regimes. Despite suffering significant cardiovascular risk, there has
been little study of platelet activation in high risk vascular surgical
patients. The potential for adverse bleeding would seem greater for
patients undergoing open surgery under antiplatelet therapy. Conse-
quently, any large scale trial powered to examine clinical end points
should be justified by “pilot” data suggesting that some cardiovas-
cular benefit could be achieved without excessive bleeding.
Through the use of surrogate biomarkers, we have demon-
strated the potential benefits of dual antiplatelet therapy in the
peri-operative period. Clopidogrel reduced sensitive markers of
platelet activation (Fig. 2) that are associated with increased clinical
risk as well as the progression of atherothrombosis.11–17,28,29 Al-
though clopidogrel did not have an overall effect on the number of
peri-operative troponin-positive events (8 clopidogrel vs. 10 pla-
cebo; P  0.86), half of the troponin elevations occurred preoper-
atively and prior to the administration of the study medication.
Subsequent institution of clopidogrel therapy was associated with a
marked reduction in troponin concentrations (Fig. 3). However, we
readily acknowledge that our study was not primarily powered to
assess cardiac troponin and clinical outcomes and whether these
improvements in surrogate biomarkers translate into clinical benefit
remains to be established.
All therapies have potential benefits and risks, and it is
inevitable that antiplatelet therapies will be associated with in-
creased bleeding complications. Although it may be regarded as
potentially reversible, the importance of major bleeding must not be
underestimated as it remains an independent predictor of adverse
clinical outcome.30–32 Although vascular patients are at high risk of
cardiovascular events, bleeding concerns are a major disincentive
for the investigation of perioperative intensive antiplatelet regimes,
and perhaps underlie the paucity of such data. Most published
reports are observational,33,34 although randomized-controlled trials
of dual antiplatelet therapy have been performed in patients under-
going carotid endarterectomy35 and peripheral angioplasty,36 and
report no major increase in bleeding complications. However, there
have been no randomized-controlled trials of dual antiplatelet ther-
apy in surgery for critical limb ischemia, where the potential for both
perioperative bleeding and cardiac complications is greater. We
have successfully delivered such a trial and confirmed that while
bleeding is increased, there was no excess of life-threatening bleeds,
reoperations, or wound infections. Our results are consistent those
reported by the CURE trial,10 where those patients who continued
clopidogrel therapy within 5 days of coronary artery bypass had a 2-fold
increased relative risk of major bleeding. Arguably our pilot data
suggests that the bleeding risks of dual antiplatelet therapy in the
peri-operative period are modest, and perhaps often over estimated.
Increasingly patients are undergoing surgery for critical limb
ischemia with a recent history of a cerebrovascular event, acute
coronary syndrome, or percutaneous coronary intervention, and will
be receiving intensive antiplatelet regimes. Their perioperative man-
agement must protect them from both coexisting pathology as well
as the associated risks of surgery. Our study has shown that it is
feasible to perform vascular surgery for critical limb ischemia, under
dual antiplatelet therapy with an acceptable bleeding profile. Although
the absolute clinical benefits of such a regimen need to be validated in
a large-scale clinical trial, we believe that our study provides evidence
for the beneficial role of perioperative antiplatelet agents in protecting
these patients against cardiovascular complications.
Patients receiving epidural or spinal anesthesia were not
recruited into the study due to the theoretical risk of epidural
hematoma. We are aware that many vascular units aim for epidural
or spinal anesthesia, thus precluding many patients from perioper-
ative antiplatelet therapy. However, there is currently no level-one
evidence for superior cardiovascular outcome with neuraxial block-
ade compared with general anesthesia. The main benefit lies in
reducing respiratory complications associated with abdominal sur-
gery.37 Although many of the patients who were recruited smoked,
none had significant chronic obstructive airway disease (based on
lung function testing) and none were undergoing abdominal or
emergency surgery. Use of both trial medication and general anes-
thesia was therefore deemed appropriate.
Persistent platelet reactivity despite antiplatelet therapy has
been proposed as a risk factor for the recurrence of ischemic events
following PCI. Recent mechanistic and clinical data suggest that
higher loading and maintenance doses of clopidogrel may achieve a
more rapid and greater degree of platelet inhibition that translates
into improved clinical outcomes, but this is yet to be formally
evaluated in an adequately powered randomized trial.38 We admin-
istered a relatively high preoperative loading dose of clopidogrel
(600 mg) to ensure efficacy of the intervention during surgery. It was
hypothesized that if additional perioperative antiplatelet therapy was
to be of any therapeutic advantage then this should be demonstrated
with the largest degree of platelet inhibition. Previous studies have
reported increased platelet activation29,39–42 and cardiovascular
events occurring within the first 5 days following surgery. We
therefore rationalized that clopidogrel therapy would be of most
benefit when given preoperatively and continued in the immediate
postoperative period. It is possible that we could still achieve
atherothrombotic protection with reduced bleeding complications by
administering lower doses of clopidogrel and this requires further
clarification. However, given the relatively high incidence of tropo-
nin-positive events before surgery, we would recommend initiation
of therapy prior to surgery.
In conclusion, we have demonstrated that perioperative dual
antiplatelet therapy has beneficial effects on reducing biomarkers of
atherothrombosis without increasing life-threatening bleeds in pa-
tients with critical limb ischemia. We propose that large-scale
randomized controlled trials are needed to establish whether dual
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antiplatelet therapy can improve clinical outcomes in high-risk
patients undergoing vascular surgery.
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